Abstract
The aryl hydrocarbon receptor (AHR) is a ligand-regulated transcription factor that can be activated by structurally diverse chemicals, ranging from environmental carcinogens to dietary metabolites. Evidence supporting a necessary role for the AHR in normal biology has been established; however, identification of key endogenous ligand/activator remains to be established. Here, we report the ability of 12(R)-hydroxy-5(Z),8(Z),10(E), 14(Z)-eicosatetraenoic acid [12(R)-HETE], an arachidonic acid metabolite produced by either a lipoxygenase or cytochrome P-450 pathway, to act as a potent indirect modulator of the AHR pathway. In contrast, structurally similar HETE isomers failed to demonstrate significant activation of the AHR. Electrophoretic mobility shift assays, together with ligand competition binding experiments, have demonstrated the inability of 12(R)-HETE to directly bind or directly activate the AHR to a DNA binding species in vitro. However, cell-based xenobiotic-responsive element-driven luciferase reporter assays indicate the ability of 12(R)-HETE to modulate AHR activity, and quantitation of induction of an AHR target gene confirmed 12(R)-HETE's ability to activate AHR-mediated transcription, even at high nanomolar concentrations in human hepatoma (HepG2)- and keratinocyte (HaCaT)-derived cell lines. One explanation for these results is that a metabolite of 12(R)-HETE is acting as a direct ligand for the AHR. However, several known metabolites failed to exhibit AHR activity. The ability of 12(R)-HETE to activate AHR target genes required receptor expression. These results indicate that 12(R)-HETE can serve as a potent activator of AHR activity and suggest that in normal and inflammatory disease conditions in skin, 12(R)-HETE is produced, perhaps leading to AHR activation.
Footnotes
-
This work was supported by National Institutes of Health grant ES04869 and a grant from Phillip Morris USA Inc. and Philip Morris International.
-
ABBREVIATIONS: AHR, aryl hydrocarbon receptor; ARNT, aryl hydrocarbon receptor nuclear translocator; DMSO, dimethyl sulfoxide; HETE, hydroxyeicosatetraenoic acid; 12(R)-HETE, 12(R)-hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid; 12(S)-HETE, 12(S)-hydroxy-5(Z),8(Z),10(E), 14(Z)-eicosatetraenoic acid; XRE, xenobiotic-responsive element; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; CDTA, trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetic acid; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate; MOPS, 3-(N-morpholino)propanesulfonic acid; HPLC, high-performance liquid chromatography; siRNA, short interfering RNA; 12-KETE, 12-oxo-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic acid.
-
↵
The online version of this article (available at http://molpharm.aspetjournals.org) contains supplemental material.
- Received May 31, 2008.
- Accepted September 8, 2008.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|